Nrgene (NRGN) AI Stock Analysis

• Market Cap: 32.76M
• Dividend Yield: N/A
• Average Volume (3M): 29.12K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: -35.05%
• EPS Growth: 36.67%
• Country: IL
• Employees: 29
• Sector: Technology
• Sector Strength: 84
• Industry: Software - Application
• EPS (TTM): -0.97
• Shares Outstanding: 13,091,577
• 10 Day Avg. Volume: 80,788
• 30 Day Avg. Volume: 29,121
• PEG Ratio: 0.09
• Price to Book (P/B): 1.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.02
• Enterprise Value/Market Cap: 0.13
• Enterprise Value/Revenue: 0.56
• Enterprise Value/Gross Profit: 16.20
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: 261.00 ▼(-10.00%Downside)

The most significant factor impacting Nrgene's stock score is the weak financial performance, highlighted by declining revenue, persistent losses, and liquidity risks. Technical analysis shows mixed signals, with some short-term momentum but overall bearish trends. Valuation is poor due to negative earnings and lack of dividends, further impacting the overall score.

Nrgene Business Overview & Revenue Model

Company Description

NRGene (NRGN) is a genomics company specializing in the development of advanced computational tools and solutions for breeding and genomic research. The company operates primarily in the agricultural sector, where it focuses on enhancing crop yield, quality, and resilience through genomic insights. NRGene's core products and services include genomic data analysis, breeding simulation, and trait discovery, which help agricultural companies and research institutions optimize their breeding programs and improve crop performance.

How the Company Makes Money

NRGene makes money through a combination of software licensing, service agreements, and collaborative partnerships. The company's revenue model is built around licensing its genomic analysis software and tools to agricultural companies, research institutions, and seed manufacturers. These entities pay for access to NRGene's advanced computational platforms, which facilitate efficient and effective breeding processes. Additionally, NRGene generates income through service contracts, offering bespoke genomic analysis and consulting services to tailor solutions for specific customer needs. Strategic partnerships and collaborations with key players in the agricultural industry also contribute to NRGene's earnings, as these alliances often involve co-development projects and shared revenue opportunities from new discoveries and advancements.

Nrgene Financial Statement Overview

Summary

Nrgene is facing significant financial challenges, including declining revenue, negative net income margins, and persistent negative cash flows, indicating operational inefficiencies and liquidity risks.

Income Statement

The company has experienced a consistent decline in revenue over the past several years, with a significant decrease from $7.6M in 2019 to $1.29M in 2024. Both EBIT and net income margins are negative, indicating ongoing operational and profitability challenges. The gross profit margin has also been declining, highlighting increased cost pressures or reduced pricing power. These factors collectively suggest weak income statement performance.

Balance Sheet

The balance sheet shows a relatively stable equity base, but the debt-to-equity ratio has improved significantly from negative equity positions in earlier years to a more balanced structure in 2024. However, the equity ratio remains low, indicating a high level of liabilities relative to assets. While the company has managed to reduce total debt, the overall financial health remains fragile.

Cash Flow

The company has consistently reported negative operating and free cash flows, suggesting challenges in generating cash from core operations. The free cash flow has further declined in recent years, reflecting increased capital expenditure or reduced cash generation. The operating cash flow to net income ratio remains negative, indicating cash flow issues. Overall, cash flow performance is poor, with significant risks to liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.29M	2.00M	3.16M	4.46M	7.04M
Gross Profit	267.00K	901.00K	1.71M	2.46M	4.51M
EBITDA	-2.69M	-4.53M	-5.59M	-7.66M	-1.75M
Net Income	-3.36M	-5.24M	-6.21M	-8.34M	-3.15M
Balance Sheet
Total Assets	6.00M	10.79M	17.30M	26.36M	3.80M
Cash, Cash Equivalents and Short-Term Investments	1.37M	6.45M	12.28M	8.85M	1.48M
Total Debt	288.00K	797.00K	791.00K	3.34M	5.08M
Total Liabilities	2.00M	3.57M	5.04M	8.68M	9.33M
Stockholders Equity	3.96M	7.21M	12.26M	17.68M	-5.53M
Cash Flow
Free Cash Flow	-5.19M	-5.58M	-7.83M	-6.67M	-1.44M
Operating Cash Flow	-3.56M	-3.91M	-6.12M	-5.57M	-1.42M
Investing Cash Flow	-1.30M	-1.27M	12.47M	-14.83M	-33.00K
Financing Cash Flow	-317.00K	-410.00K	-2.46M	27.59M	326.00K

Nrgene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 290.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Negative. The current price of 290 is above the 20-day moving average (MA) of 262.57, above the 50-day MA of 273.14, and below the 200-day MA of 304.69, indicating a bearish trend. The MACD of 1.30 indicates Negative momentum. The RSI at 44.93 is Neutral, neither overbought nor oversold. The STOCH value of 47.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:NRGN.

Nrgene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONE	77 Outperform	6.33B	26.56		8.84%	10.20%	25.17%
MTRX	76 Outperform	7.77B	27.80		2.97%	5.14%	18.71%
ABRA	71 Outperform	394.23M	27.83		―	―	―
Sector *	63 Neutral	$33.24B	5.92	-11.55%	1.90%	5.54%	-20.14%
NRGN	46 Neutral	32.76M	―		―	-35.05%	36.67%